Fund Details
Overview
Investment portfolio
13rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Orange Dental | Jan 2024Led | $130 MSeries B | |
SVOLT | Aug 2021Participated | $1.6 BSeries B | |
Hepagene Therapeutics | Apr 2021Participated | $40 MSeries B | |
Immune-Onc Therapeutics | Mar 2021Led | $73 MSeries B | |
LakeShore Biopharma | Mar 2021Led | $130 MSeries B | |
Teon Therapeutics | Feb 2021Led | $30 MSeries A | |
Creative Biosciences | Sep 2020Participated | $88 MSeries C | |
Triumvira Immunologics | Aug 2020Participated | $55 MSeries A | |
HireEZ | Aug 2020Led | $13 MSeries B | |
Apexigen | Mar 2020Led | $65 MSeries C | |
Ansun BioPharma | Oct 2019Led | $8 MSeries B | |
Inspirna | Oct 2018Participated | $40 MSeries C | |
Orange Dental | Jan 2024Led | $130 MSeries B | |
SVOLT | Aug 2021Participated | $1.6 BSeries B | |
Hepagene Therapeutics | Apr 2021Participated | $40 MSeries B | |
Immune-Onc Therapeutics | Mar 2021Led | $73 MSeries B | |
LakeShore Biopharma | Mar 2021Led | $130 MSeries B | |
Teon Therapeutics | Feb 2021Led | $30 MSeries A | |
Creative Biosciences | Sep 2020Participated | $88 MSeries C | |
Triumvira Immunologics | Aug 2020Participated | $55 MSeries A | |
HireEZ | Aug 2020Led | $13 MSeries B | |
Apexigen | Mar 2020Led | $65 MSeries C | |
Ansun BioPharma | Oct 2019Led | $8 MSeries B | |
Inspirna | Oct 2018Participated | $40 MSeries C |
13 Items
13
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 1 | 2 |
| Series B | 5 | 2 |
| Series C+ | 1 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| May '18 | 1 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 1 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 1 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 1 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 2 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 1 |
| Mar '21 | 2 |
| Apr '21 | 1 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 1 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 11 |
| Enterprise Software | 1 |
| Manufacturing | 1 |
| AI & Machine Learning | 1 |
| Clean Energy & Sustainability | 1 |
| Professional Services | 1 |
| Data, Analytics & IT | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 1 |
| $25M-$50M | 3 |
| $50M-$100M | 5 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 1 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 8 |
| China | 4 |
| Hong Kong | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| 3W Capital | 2 |
| Adjuvant Capital | 2 |
| AIHC Capital | 2 |
| Eight Roads Ventures | 2 |
| F-Prime Capital | 2 |
| Haitong International | 2 |
| IDG Capital | 2 |
| MSA Capital | 2 |
| Northern Light Venture Capital | 2 |
| OrbiMed | 2 |
| Superstring Capital | 2 |
| 3E Bioventures Capital | 1 |
| Alexandria Venture Investments | 1 |
| Apricot Capital | 1 |
| Bank of China Group Investment | 1 |
| Bloom Burton & Co. | 1 |
| CCB International | 1 |
| CDH Investments | 1 |
| Centre for Commercialization of Cancer Immunotherapy | 1 |
| China Renaissance | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 7 | 54% |
| Participating | 6 | 46% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 43% |
| Co-led | 4 | 57% |
Team
Adam Sun
Managing Partner
Dave Chenn
Chief executive officer
Dongjun Ma
Managing Partner
Shirley Hu
Managing Director